BridgeMD
A Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants with Juvenile Psoriatic Arthritis
EU CTIS ID: 2024-517262-41-00
What this study is testing
The main goal of this study is to see if deucravacitinib works better than a placebo in kids and teenagers between the ages of 5 and 18 who have Juvenile Psoriatic Arthritis (JPsA).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants need to have been diagnosed with JPsA. This means a participant has arthritis and skin problems like Psoriasis (PsO), or arthritis with other symptoms like swollen fingers or toes (dactylitis), changes in nails, or a close family member with PsO.
- Participants need to have at least three joints that are affected by arthritis. This could mean that these joints are swollen, painful, or don't move as well as they should.
- Participants should have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems
- Participants need to have been diagnosed with JPsA. This means a participant has arthritis and skin problems like Psoriasis (PsO), or arthritis with other symptoms like swollen fingers or toes (dactylitis), changes in nails, or a close family member with PsO.
- Participants need to have at least three joints that are affected by arthritis. This could mean that these joints are swollen, painful, or don't move as well as they should.
- Participants should have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems
You likely can't join if
- Diagnosis of JPsA before 5 years of age, or certain substances in the blood like Antinuclear Antibodies (ANA) or Rheumatoid Factor (RF) above a certain level.
- Have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA.
- Have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months
- Diagnosis of JPsA before 5 years of age, or certain substances in the blood like Antinuclear Antibodies (ANA) or Rheumatoid Factor (RF) above a certain level.
- Have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA.
- Have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months
The study team makes the final eligibility decision.
Where it's taking place
- Brazil
- Turkey
- United States
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Brazil; Turkey; United States; China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.